Autopsy report · NCT03282669

TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia

“Change in institutional policy. Change in resources available.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Northwestern University

Sponsor type

University, hospital or other

Conditions

Pain, Postoperative; Obesity; Respiratory Insufficiency

Interventions

Intrathecal Morphine; Intravenous hydromorphone

Participants

0

Trials that died the same way

• Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients
  “Institutional Issue” (68% match in meaning)
• The Phosphodiesterase Inhibitor Tadalafil as an Adjunct to Antidepressants in Major Depressive Disorder Patients
  “Institutional and funding constrains” (60% match in meaning)
• Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks
  “Funding changes.” (58% match in meaning)
• Very Small Embryonic-like Stem Cells for Knee Osteoarthritis
  “Policy changes have contributed to the failure to carry out smoothly” (57% match in meaning)
• A Prospective Study of the NUVANCE Facial Rejuvenation System for Mid-Face, Neck and Jowl Rejuvenation Procedures
  “Change in business priorities.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.